ELI LILLY Aktie

 

Der US-amerikanische Pharma-Konzern hat sich in diesem Jahr bereits mit jeder Menge an Zukäufen verstärkt. Und das Unternehmen hält die Schlagzahl hoch: Mit einem chinesischen Pharma-Konzern ist Eli Lilly einen neuen milliardenschweren Deal eingegangen....

UBS published a research report saying that INNOCARE (09969.HK) and Eli Lilly and Company (LLY.US) reached a collaboration agreement on the discovery and development of up to five innovative target projects. The broker held a positive view on the deal, believing it recognizes the company's R&D capabilities.The broker noted that ......

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations....

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading....

Eli Lilly's CEO says 700,000 seniors have begun taking GLP-1s since Medicare's July coverage launched, and most chose Lilly. What it means for LLY stock....

INDIANAPOLIS (dpa-AFX) - Thursday, Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration has approved Onswik, a once-weekly basal insulin injection, for treatment of adu......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE (09969.HK) closed down 4.76% at midday today (24th). The stock once surged in the afternoon session and briefly turned higher by 2.6% to a peak of HKD16.16, but later fell sharply again. It is now trading at HKD14.13, down 10.29%, with trading volume of 18.4012 million shares, involving turnover of HKD274 million.INNOCA......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE (09969.HK) announced that it has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company (LLY.US) for new drug development.Under the agreement, INNOCARE will leverage its proprietary drug development platform and extensive research experience to develop and advance compounds ta......

The company continues to dominate the weight loss market....

Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong....

Der Ozempic-Konzern hat gegen Eli Lilly viel Boden verloren und will nun bei Haarausfall-Mitteln angreifen. Ob das reicht, um verlorenes Anlegervertrauen zurückzuholen? Der dänische Pharmakonzern Novo Nordisk richtet sich strategisch neu aus. Der Hersteller von Ozempic und Wegovy prüft einen Einstieg in den Markt für Mittel gegen Haarausfall, wie Bloomberg berichtete. Zugleich zeigte sich Vorstandschef Mike Doustdar gegenüber der Financial ......

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest Portfolios Group Inc. (“Harvest”) announces the following distributions for Harvest High Income Shares ETFs TM for the month ending September 30, 2026. The distribution will be paid on or about October 6, 2026 to securityholders of record on September 29, 2026, with an ex-dividend date of September 29, 2026. Harvest High Income Shares ETF Ticker* Distribution Harvest Eli Lilly High Income Shares ETF LLYH $0.1400 per unit Harvest Eli Lilly High Income Shares ETF (US) LLYH.U $0.1400 per unit Harvest Amazon High Income Shares ETF AMZH $0.1600 per unit Harvest Amazon High Income Shares ETF (US) AMZH.U $0.1600 per unit Harvest Microsoft High Income Shares ETF MSFH $0.1200 per unit Harvest Microsoft High Income Shares ETF (US) MSFH.U $0.1200 per unit Harvest NVIDIA High Income Shares ETF NVDH $0.2000 per unit Harvest NVIDIA High Income Shares ETF (US) NVDH.U $0.1900 per unit Harvest Eli Lilly Enhanced High Income Shares ETF LLHE $0.1650 per unit Harvest Eli Lilly ...

With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Medicare coverage opens the obesity pill market to millions more Americans....

Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger....

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk....

NVO's CagriSema delivers greater weight loss than Eli Lilly's tirzepatide in T2D and 21% weight loss in obesity, strengthening its late-stage pipeline....